关注
Franco Maggiolo
Franco Maggiolo
ASST Papa Giovanni XXIII
在 asst-pg23.it 的电子邮件经过验证
标题
引用次数
引用次数
年份
Dolutegravir plus abacavir–lamivudine for the treatment of HIV-1 infection
SL Walmsley, A Antela, N Clumeck, D Duiculescu, A Eberhard, ...
New England Journal of Medicine 369 (19), 1807-1818, 2013
10212013
Mapping the human genetic architecture of COVID-19
Writing group Writing group leaders Pathak Gita A. 6 Andrews Shea J. 7 Kanai ...
Nature 600 (7889), 472-477, 2021
7452021
Dolutegravir in antiretroviral-experienced patients with raltegravir-and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study
A Castagna, F Maggiolo, G Penco, D Wright, A Mills, R Grossberg, ...
The Journal of infectious diseases 210 (3), 354-362, 2014
4252014
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2 …
P Cahn, JS Madero, JR Arribas, A Antinori, R Ortiz, AE Clarke, CC Hung, ...
The Lancet 393 (10167), 143-155, 2019
4082019
Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised …
J van Lunzen, F Maggiolo, JR Arribas, A Rakhmanova, P Yeni, B Young, ...
The Lancet infectious diseases 12 (2), 111-118, 2012
3782012
Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors
F Maggiolo, L Ravasio, D Ripamonti, G Gregis, G Quinzan, C Arici, ...
Clinical infectious diseases 40 (1), 158-163, 2005
3072005
One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects
M Airoldi, M Zaccarelli, L Bisi, T Bini, A Antinori, C Mussini, F Bai, ...
Patient preference and adherence, 115-125, 2010
2672010
Whole-genome sequencing reveals host factors underlying critical COVID-19
A Kousathanas, E Pairo-Castineira, K Rawlik, A Stuckey, CA Odhams, ...
Nature 607 (7917), 97-103, 2022
2382022
Cytomegalovirus coinfection is associated with an increased risk of severe non–AIDS-defining events in a large cohort of HIV-infected patients
M Lichtner, P Cicconi, S Vita, A Cozzi-Lepri, M Galli, S Lo Caputo, ...
The Journal of infectious diseases 211 (2), 178-186, 2015
2182015
Age at infection affects the long-term outcome of transfusion-associated chronic hepatitis C
E Minola, D Prati, F Suter, F Maggiolo, F Caprioli, A Sonzogni, M Fraquelli, ...
Blood, The Journal of the American Society of Hematology 99 (12), 4588-4591, 2002
2142002
Effect of adherence to HAART on virologic outcome and on the selection of resistance-conferring mutations in NNRTI-or PI-treated patients
F Maggiolo, M Airoldi, HD Kleinloog, A Callegaro, V Ravasio, C Arici, ...
HIV clinical trials 8 (5), 282-292, 2007
1932007
Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males: findings from a nested case-control study
C Fallerini, S Daga, S Mantovani, E Benetti, N Picchiotti, D Francisci, ...
elife 10, e67569, 2021
1792021
Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trial
F Maggiolo, D Ripamonti, G Gregis, G Quinzan, A Callegaro, F Suter
Aids 18 (3), 439-446, 2004
1622004
Efavirenz: a decade of clinical experience in the treatment of HIV
F Maggiolo
Journal of Antimicrobial Chemotherapy 64 (5), 910-928, 2009
1542009
Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 …
A Cozzi-Lepri, M Noguera-Julian, F Di Giallonardo, R Schuurman, ...
Journal of antimicrobial chemotherapy 70 (3), 930-940, 2015
1442015
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C
R D'Ambrosio, L Pasulo, M Puoti, M Vinci, M Schiavini, S Lazzaroni, ...
Journal of hepatology 70 (3), 379-387, 2019
1422019
Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide for initial treatment of HIV-1 infection …
HJ Stellbrink, JR Arribas, JL Stephens, H Albrecht, PE Sax, F Maggiolo, ...
The lancet HIV 6 (6), e364-e372, 2019
1412019
Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated …
C Orrell, DP Hagins, E Belonosova, N Porteiro, S Walmsley, V Falcó, ...
The Lancet HIV 4 (12), e536-e546, 2017
1382017
Simpler regimens may enhance adherence to antiretrovirals in HIV-infected patients
M Franco, R Diego, A Claudio, G Giampietro, Q Giampaolo, ...
HIV Clinical Trials 3 (5), 371-378, 2002
1272002
Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer
D Ripamonti, D Cattaneo, F Maggiolo, M Airoldi, L Frigerio, P Bertuletti, ...
Aids 21 (18), 2409-2415, 2007
1162007
系统目前无法执行此操作,请稍后再试。
文章 1–20